Targeting of VEGF with the receptor-tyrosine kinase (RTK) inhibitor Sunitinib has been shown to be effective in NB metastatic cell treatment, but no change in resistance to this therapy has been found in clinic [92]. Here, VEGFA is linked to neuroblastoma.